Immunome (IMNM) Income from Continuing Operations (2019 - 2026)
Immunome's (IMNM) quarterly Income from Continuing Operations came in at 244246000.0 in Q1 2026, down 443.98% YoY from 71006341.37 in Q1 2025, and down 235.2% on a QoQ basis from 72866000.0 in Q4 2025.
Powered by 
Analysis
Immunome (IMNM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Income from Continuing Operations data on file, last reported at 244246000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 443.98% year-over-year to 244246000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 489318000.0 (down 48.04% YoY) and the FY2025 annual result came in at 404781000.0, up 1.88% from the prior year.
- Income from Continuing Operations slipped to 244246000.0 in Q1 2026, from 72866000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4571000.0 in Q1 2023 to a low of 244246000.0 in Q1 2026.
- A 5-year average of 66231176.47 and a median of 70303000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 2796.5% — and 2025, when it surged 66.09%.
- Tracing IMNM's Income from Continuing Operations over 5 years: stood at 8079000.0 in 2022, then slumped by 1072.36% to 94715000.0 in 2023, then increased by 12.08% to 83270000.0 in 2024, then rose by 12.49% to 72866000.0 in 2025, then tumbled by 235.2% to 244246000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 244246000.0 (Q1 2026), 72866000.0 (Q4 2025), and 101903000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunome | 3.03 Bn | 2.51 Bn | - | -78.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -78.14 Mn |
| Mar 31, 2026 | -59.33 Mn |
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -60.14 Mn |
| Jun 30, 2025 | -46.48 Mn |
| Mar 31, 2025 | -44.64 Mn |
| Dec 31, 2024 | -82.97 Mn |
| Sep 30, 2024 | -50.52 Mn |
| Jun 30, 2024 | -40.01 Mn |
| Mar 31, 2024 | -132.30 Mn |
| Dec 31, 2023 | -94.65 Mn |
| Sep 30, 2023 | -4.63 Mn |
| Jun 30, 2023 | -5.77 Mn |
| Mar 31, 2023 | -4.47 Mn |
| Dec 31, 2022 | -7.79 Mn |
| Sep 30, 2022 | -8.53 Mn |
| Jun 30, 2022 | -8.93 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Dec 31, 2021 | -7.84 Mn |
| Sep 30, 2021 | -7.72 Mn |